Blood-based biomarkers and plasma Aβ assays in the differential diagnosis of Alzheimer’s disease and behavioral-variant frontotemporal dementia
We introduced a novel IP-MS assay that demonstrated comparable precision to the Shimadzu composite score in differentiating AD from non-neurodegenerative control groups. However, Aβ levels did not enhance the discrimination between AD and bvFTD. Furthermore, our findings support the utility of combining pTau181 and GFAP as a robust strategy for the blood-based differentiation of AD and bvFTD.
Authors
- Sylvain Lehmann (ORCID: https://orcid.org/0000-0001-6117-562X)
- Jana Kindermans (ORCID: https://orcid.org/0000-0001-6218-7753)
- Christophe Hirtz (ORCID: https://orcid.org/0000-0002-7313-0629)
- Jérôme Vialaret (ORCID: https://orcid.org/0000-0002-3730-2366)
- Patrick Oeckl (ORCID: https://orcid.org/0000-0002-7652-7023)
- Pablo Mohaupt (ORCID: https://orcid.org/0000-0002-8887-7119)
- Markus Otto (ORCID: https://orcid.org/0000-0003-4273-4267)
- Sarah Anderl-Straub
- Leonie Werner
Institutions
- Inserm (FR)
- Université de Montpellier (FR)
- German Center for Neurodegenerative Diseases (DE)
- University Hospital Ulm (DE)
- Martin Luther University Halle-Wittenberg (DE)
Publication Details
- Journal
- Alzheimer s Research & Therapy
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1186/s13195-024-01647-w
- Citations
- 9
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 3.47